Recently, according to the official WeChat account of Wuhan Weike Medical Technology Co., Ltd. (hereinafter referred to as Weike Medical), Weike Medical has successfully completed its Series C financing, with a financing amount of hundreds of millions of yuan, fully led by Bohua Capital, a well-known investment institution in Liangxi District, Wuxi City.

It is reported that this round of financing will provide strong financial support for Weike Medical in product research and development, market expansion, and international strategic layout.

According to the Yaozhi Data Investment Pattern Database, Weike Medical has successfully completed four rounds of financing in the three years from 2019 to 2021, with the highest amount being the B-round financing of hundreds of millions of RMB on December 16, 2021, promoting the research and innovation of multiple minimally invasive intervention products, accelerating the product registration and listing process, and bringing better treatment solutions to the vast number of structural heart disease patients in China as soon as possible.

Weike Medical was established in July 2018, focusing on major clinical needs in the cardiovascular field, especially in the field of minimally invasive interventions for heart failure and structural heart disease. Committed to creating an innovative medical device platform for cardiovascular full cycle solutions through research and development, technical services, production, and sales, providing more optimized products and treatment plans for doctors and patients worldwide.

At present, Weike Medical has applied for more than 80 patents, including over 60 invention patents, 10 utility model patents, and 3 PCT patents. The related products have complete independent intellectual property rights. The atrial shunt has obtained NMPA's "Innovative Medical Device Special Review Procedure" and FDA's "Breakthrough Medical Device Certification".

According to research firm IQVIA, the global cardiovascular medical device market size was 59.3 billion US dollars in 2021, with the domestic cardiovascular market size exceeding 50 billion yuan, ranking second in both the global and domestic medical device markets, second only to the in vitro diagnostic field.

The continuous expansion of the cardiovascular market has also brought huge development opportunities for equipment companies such as Weike Medical. In this context, Weike Medical has successfully launched multiple innovative products with its outstanding research and development capabilities and market insights.

According to the official website of Weike Medical, its product line covers multiple areas of cardiovascular treatment, including atrial shunts and various active devices for heart failure prevention and treatment, patent foramen ovale occluder for preventing cardiogenic stroke, transcatheter aortic valve replacement system for treating valve diseases, as well as related surgical accessories and consumables.

Among them, D-shufo ™ The patent foramen ovale occluder was registered and approved by NMPA in February 2024. This product is also the third domestically produced patent foramen ovale occluder approved for market in China, with multiple product advantages: Using mature nickel titanium alloy wire as raw material, excellent shape memory and resilience provide stable clamping effect. After 20 years of clinical verification, its safety and stability are highly trusted;
Parylene surface coating technology effectively blocks the release of nickel ions and reduces allergic reactions; The disc-shaped internal buckle structure tightly adheres to the inter chamber space after release, reducing residual flow; The left disc is designed without rivets to promote endothelialization and reduce the occurrence of left heart thrombus; 12 specifications and models, finely adjusting the diameter of the disc and waist, unique disc specifications with large left and small right, can adapt to complex shapes of patent foramen ovale and improve the success rate of occlusion.

In addition, two other products under development by Weike Medical are also being continuously promoted.

 D-shant ® Atrial shunt
D-shant ® The atrial shunt has previously been included in the national innovation medical device approval green channel and was granted the "breakthrough medical device" certification by the FDA in November 2023. It is used to treat patients with moderate to severe chronic heart failure, reduced ejection fraction (HFrEF), high left atrial pressure, and a recent history of ineffective standardized drug treatment, becoming the first atrial shunt product approved in China.

D-shant ® Atrial shunt with its intervention being recyclable and requiring secondary intervention; Internal buckle disc design, eccentric horizontal placement of nuts; The unique advantages of stronger radial support force and multi specification shunt aperture have brought new solutions for heart failure treatment, successfully solving the pain points of traditional treatment.

 DOCS VALVE ® Transcatheter aortic valve replacement system
DOCS VALVE ® Another core product of Weike Medical's Transcatheter Aortic Valve Replacement System not only integrates high clinical efficacy and smooth operating experience, but also achieves significant technological breakthroughs.

Its biggest clinical advantage lies in breaking through the contraindications of large annulus and simple reflux, meeting the dual indications of stenosis and reflux. More noteworthy is that, DOCS VALVE ® By implementing a coaxial adjustment strategy for the aortic root, there is no need for rapid pacing or general anesthesia sedation, avoiding the risk of circulatory collapse and making the surgical process safer and simpler. Minimally invasive intervention is used, and the surgery can be completed in just 40 minutes. This innovative design will bring broader prospects for heart valve replacement surgery.

Regarding this financing, Wang Xueli, co-founder and CEO of Weike Medical, said, "Weike Medical will continue to focus on the clinical needs in the cardiovascular field, especially minimally invasive intervention therapy for heart failure and structural heart disease. At the same time, we will strengthen cooperation with medical institutions, research institutions, and upstream and downstream industries to jointly build an innovative ecosystem in the cardiovascular medical field and contribute to the sustainable development of the industry

Source: https://news.yaozh.com/archive/44731.html